Median Technologies to Present AI-Powered Central Imaging and iCRO Services for Oncology Clinical Trials at ASCO 2026 Annual Meeting
Median Technologies, a global leader in AI-powered imaging analytics and central imaging services for oncology clinical trials, has announced its participation in the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will showcase its latest innovations in radiopharmaceutical image processing and cachexia assessment, reinforcing its position at the intersection of artificial intelligence, medical imaging, and oncology drug development.
The ASCO Annual Meeting is widely recognized as the world’s most influential oncology conference, bringing together more than 35,000 oncology professionals, researchers, clinicians, and industry leaders from across the globe. Hosted by the American Society of Clinical Oncology and held at McCormick Place in Chicago, Illinois, the 2026 edition of the meeting will take place from May 29 to June 2. The exhibition portion, where Median Technologies will participate, will run from May 30 to June 1.
Median Technologies will be present at booth #36102 in the South Building, Hall A, McCormick Place. Throughout the exhibition days, the company will engage with pharmaceutical partners, oncology researchers, and clinical trial stakeholders, demonstrating how its imaging solutions are transforming oncology drug development. The booth will be open daily from 9:00 AM to 5:00 PM Central Time.
Strengthening Leadership in AI-Powered Oncology Imaging
Median Technologies has established itself as a key global provider of imaging services for oncology clinical trials. Its core expertise lies in central imaging review, image analysis, and AI-driven imaging biomarkers that support biopharmaceutical companies in accelerating clinical development and improving the accuracy of oncology trial outcomes.
The company’s platform integrates advanced artificial intelligence and machine learning technologies to provide standardized, high-quality imaging analysis across global clinical trial networks. These capabilities are particularly important in oncology research, where imaging plays a critical role in assessing tumor response, disease progression, and therapeutic efficacy.
At ASCO 2026, Median Technologies will highlight how its imaging services are evolving to meet the growing complexity of oncology drug development, especially in emerging therapeutic areas such as radiopharmaceuticals and cancer-associated cachexia.
Introduction of New Radiopharmaceutical Imaging Solutions
One of the key highlights of Median’s participation at ASCO 2026 will be the introduction of its new radiopharmaceutical image processing solutions. Radiopharmaceutical therapies are becoming increasingly important in oncology, offering targeted treatment approaches that combine diagnostic imaging with therapeutic delivery.
However, these therapies also require highly specialized imaging analysis to evaluate drug distribution, tumor targeting, and treatment response. Median Technologies is addressing this need by introducing AI-powered imaging workflows designed specifically for radiopharmaceutical clinical trials.
The company’s solutions aim to improve accuracy in quantifying radiotracer uptake, standardize image interpretation across multiple trial sites, and reduce variability in imaging endpoints. By leveraging artificial intelligence, Median’s platform supports faster and more reliable decision-making in clinical studies, helping pharmaceutical companies optimize trial design and accelerate regulatory pathways.
At booth #36102, attendees will have the opportunity to learn about how these innovations are being applied in real-world oncology studies and how they can enhance trial efficiency and data quality.
Advancing Cachexia Assessment Through Body Composition Analysis
Another major focus for Median Technologies at ASCO 2026 is its new solution for cachexia assessment in oncology patients. Cancer cachexia is a complex metabolic syndrome characterized by weight loss, muscle wasting, and reduced quality of life. It is commonly observed in patients with advanced cancer and can significantly impact treatment outcomes.
Median Technologies’ new approach uses AI-driven body composition analysis to evaluate cachexia more precisely in clinical trial populations. By analyzing medical imaging data, the solution can quantify muscle mass, fat distribution, and other physiological markers associated with cachexia progression.
This technology provides oncology researchers with a more objective and reproducible method for assessing patient condition, beyond traditional weight-based measurements. It also supports better stratification of patients in clinical trials and enables more accurate evaluation of therapeutic interventions aimed at improving patient quality of life.
During the ASCO exhibition, Median will host a dedicated presentation session on this topic, highlighting how AI-enabled imaging biomarkers are advancing cachexia research and improving patient-centric endpoints in oncology trials.
Educational Presentation Sessions at ASCO 2026
In addition to its exhibition presence, Median Technologies will host two expert-led presentation sessions at its booth. These sessions are designed to provide deeper insights into the company’s latest technological advancements and their application in oncology research.
The first session, titled “Unlocking Oncology Trial Potential with Radiopharmaceutical Imaging,” will take place on Saturday, May 30 from 11:30 AM to 12:00 PM. It will be presented by Antoine Iannessi, Vice President of Medical Affairs at Median’s iCRO division. This session will explore how radiopharmaceutical imaging is transforming oncology clinical trials by improving lesion detection, treatment monitoring, and quantitative imaging endpoints.
The second session, “Advancing Cachexia Assessment in Oncology Trials with Body Composition Analysis,” will be held on Sunday, May 31 from 11:30 AM to 12:00 PM. Also led by Antoine Iannessi, this presentation will focus on how AI-driven imaging analytics can provide more accurate assessments of cancer-related cachexia and improve patient outcome measurement in clinical research.
Both sessions will emphasize the role of artificial intelligence in enhancing imaging precision, reducing variability across trial sites, and supporting more robust clinical evidence generation.
Expanding the Role of AI in Oncology Clinical Trials
The participation of Median Technologies at ASCO 2026 reflects broader industry trends toward digital transformation in oncology research. As clinical trials become increasingly global and data-intensive, the need for standardized, scalable, and AI-powered imaging solutions continues to grow.
Median’s iCRO (imaging Contract Research Organization) services are designed to meet this demand by offering centralized imaging management, regulatory-compliant workflows, and advanced image analytics. These services help pharmaceutical sponsors ensure consistency in imaging endpoints, improve data quality, and accelerate time-to-market for new oncology therapies.
The company’s proprietary AI platform, including its eyonis® suite of software as a medical device (SaMD), further strengthens its capabilities in early cancer detection and imaging diagnostics. By integrating AI across both clinical trial imaging and diagnostic applications, Median is building a comprehensive ecosystem that spans the full oncology care continuum.
About ASCO 2026 Annual Meeting
ASCO Annual MeetingASCO 2026 Annual Meeting is the premier global oncology conference organized by the American Society of Clinical Oncology. The event serves as a major platform for sharing cutting-edge research, clinical trial results, and technological innovations in cancer treatment.
Each year, the meeting attracts tens of thousands of participants from academia, industry, and healthcare institutions. The 2026 edition is expected to continue this tradition, showcasing breakthroughs in immunotherapy, precision medicine, radiopharmaceuticals, and AI-driven healthcare technologies.
For companies like Median Technologies, ASCO represents a critical opportunity to engage with key stakeholders in oncology drug development, establish strategic partnerships, and demonstrate the impact of their technologies on clinical research outcomes.
Median Technologies
Median Technologies is a French-based technology company specializing in innovative software as a medical device (SaMD) and advanced imaging services for oncology. The company develops AI-powered solutions designed to improve cancer diagnosis, treatment monitoring, and clinical trial imaging analysis.
Its flagship offerings include the iCRO platform, which provides centralized imaging services for oncology clinical trials, and the eyonis® suite, which uses artificial intelligence and machine learning to support early cancer detection. The company operates globally, with a presence in Europe, the United States, and China, and serves leading pharmaceutical and biotechnology companies.
By combining medical imaging expertise with advanced AI capabilities, Median Technologies aims to improve the accuracy and efficiency of oncology research and contribute to the development of more effective cancer therapies worldwide.
The participation of Median Technologies at ASCO 2026 underscores the growing importance of AI-driven imaging solutions in oncology clinical research. Through its new innovations in radiopharmaceutical imaging and cachexia assessment, the company is addressing some of the most critical challenges in cancer drug development today.
By engaging directly with global oncology stakeholders at one of the industry’s most important conferences, Median Technologies continues to strengthen its position as a leader in AI-powered imaging services and central imaging solutions for clinical trials.
About Median Technologies:
Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market
